ArticleDiabetology & metabolic syndrome2025
Macrovascular outcomes and mortality after bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease, and Type 2 diabetes.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease globally, with a significant association between MASLD and Type 2 diabetes mellitus (T2DM), obesity, and cardiovascular disease (CVD). While bariatric surgery (BS) has showed efficacy in improving MASLD markers and reducing CVD incidence, its impact on macrovascular events and all-cause mortality in patients with obesity, MASLD, and T2DM remains understudied.
methodsThis retrospective cohort study utilized the TriNetX. Adult patients (> 18 years) with obesity (BMI ≥ 35 kg/m²), MASLD, and T2DM were included. Propensity score matching (1:1) was performed to compare patients undergoing BS with nonsurgical controls. Primary outcomes was the incidence of macrovascular disease, defined as major adverse cardiovascular events (MACE) and cerebrovascular events. Secondary outcomes was all-cause mortality. Cox proportional hazards models were used to calculate hazard ratios (HRs).
resultsA total of 53,204 patients met inclusion criteria, of which 2,463 underwent BS. After matching (2,449 surgical vs. 2,449 nonsurgical patients), BS was associated with a significantly lower risk of macrovascular events (HF: HR 0.68, 95% CI 0.51-0.90; coronary artery disease: HR 0.31, 95% CI 0.21-0.44; cerebrovascular disease: HR 0.38, 95% CI 0.25-0.57) over a mean follow-up of 5.3 years. All-cause mortality was also significantly reduced in the BS group (HR 0.30, 95% CI 0.15-0.62). Sensitivity analyses confirmed the consistency of these results.
conclusionsThis study suggeststhat bariatric surgery significantly lower risk of macrovascular events and all-cause mortality in patients with obesity, MASLD, and T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.